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Clinical Infectious Diseases
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Background. Few data exist describing pertussis epidemiology among infants and children in low- and middle-income countries
to guide preventive strategies.
Methods. Children 1–59 months of age hospitalized with World Health Organization–deﬁned severe or very severe pneumonia in 7
African and Asian countries and similarly aged community controls were enrolled in the Pneumonia Etiology Research for Child Health
study. They underwent a standardized clinical evaluation and provided nasopharyngeal and oropharyngeal swabs and induced sputum
(cases only) for Bordetella pertussis polymerase chain reaction. Risk factors and pertussis-associated clinical ﬁndings were identiﬁed.
Results. Bordetella pertussiswas detected in 53 of 4200 (1.3%) cases and 11 of 5196 (0.2%) controls. In the age stratum 1–5 months, 40
(2.3% of 1721) cases were positive, all from African sites, as were 8 (0.5% of 1617) controls. Pertussis-positive African cases 1–5 months
old, compared to controls, were more often human immunodeﬁciency virus (HIV) uninfected-exposed (adjusted odds ratio [aOR], 2.2),
unvaccinated (aOR, 3.7), underweight (aOR, 6.3), and too young to be immunized (aOR, 16.1) (all P≤ .05). Compared with pertussis-
negative African cases in this age group, pertussis-positive cases were younger, more likely to vomit (aOR, 2.6), to cough ≥14 days (aOR,
6.3), to have leukocyte counts >20 000 cells/µL (aOR, 4.6), and to have lymphocyte counts >10 000 cells/µL (aOR, 7.2) (all P≤ .05). The
case fatality ratio of pertussis-infected pneumonia cases 1–5 months of age was 12.5% (95% conﬁdence interval, 4.2%–26.8%; 5/40); per-
tussis was identiﬁed in 3.7% of 137 in-hospital deaths among African cases in this age group.
Conclusions. In the postneonatal period, pertussis causes a small fraction of hospitalized pneumonia cases and deaths; however, case
fatality is substantial. The propensity to infect unvaccinated infants and those at risk for insufﬁcient immunity (too young to be vaccinated,
premature, HIV-infected/exposed) suggests that the role for maternal vaccination should be considered along with efforts to reduce
exposure to risk factors and to optimize childhood pertussis vaccination coverage.
Keywords. pertussis; infant; pneumonia; whooping cough; vaccination.
Most deaths from pertussis occur in developing countries and
among children during the ﬁrst weeks or months of life [1].
The World Health Organization (WHO) estimated that in
2013, Bordetella pertussis caused approximately 60 257 deaths
in children <5 years of age [2].However, there is uncertainty re-
garding these estimates, largely due to the paucity of data from
the areas where most deaths occur. The variable clinical
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presentation of pertussis, especially in young infants, and the
cost and complexity of diagnostic assays compound the difﬁ-
culty in ascertaining accurate estimates. Protecting young
infants from pertussis is considered a priority [3]. To achieve
this goal, robust data on pertussis case-fatality and risk factors
are needed to guide prioritization of control strategies and
public health interventions.
The Pneumonia Etiology Research for Child Health (PERCH)
Study, described in detail elsewhere [4], provided an opportunity
to examine the clinical and epidemiologic characteristics of
pertussis among infants and young children hospitalized with
WHO-deﬁned severe and very severe pneumonia in 7 developing
countries. Here we report the pertussis ﬁndings among all
PERCH-enrolled children, with more detailed analyses of those
most at risk for pertussis, infants <6 months of age.
METHODS
Participants
Between August 2011 and January 2014, each site enrolled chil-
dren 1–59 months old into PERCH during 24 consecutive
months. Study sites included Dhaka and Matlab, Bangladesh;
Basse, The Gambia; Kiliﬁ, Kenya; Bamako, Mali; Soweto,
South Africa; Sa Kaeo and Nakhon Phanom, Thailand; and
Lusaka, Zambia. Sites, selected to represent pneumonia epide-
miology in low- and middle-income settings, contained a mix
of urban and rural populations, high and low human immuno-
deﬁciency virus (HIV) prevalence rates, and varying infant
mortality [4]. Identiﬁcation and enrollment of cases hospital-
ized with severe and very severe pneumonia have been
described [5]. Severe pneumonia was deﬁned as presence of
cough or difﬁculty breathing plus lower chest wall indrawing;
very severe pneumonia was deﬁned as cough or difﬁculty
breathing, plus at least 1 danger sign (ie, central cyanosis, difﬁ-
culty breastfeeding/drinking, vomiting everything, convulsions,
lethargy, reduced consciousness, or head nodding) [6]. Cases
were excluded if they were hospitalized within the previous 14
days, discharged as a PERCH case within the past 30 days, did
not reside in the study catchment area, or recovered from lower
chest wall indrawing following bronchodilator therapy for those
with wheeze.
Control children were enrolled year round, randomly selected
from the community serving as the catchment area for cases,
and frequency-matched to cases by enrollment date and age
within the following strata: 28 days to 5 months, 6–11 months,
12–23 months, and 24–59 months, as described [5]. Those
found to have WHO-deﬁned severe or very severe pneumonia
were ineligible and referred for medical care; those with nonse-
vere respiratory illness were eligible for enrollment.
The study protocol was approved by the institutional review
board or ethical review committee overseeing each site and at
the Johns Hopkins Bloomberg School of Public Health. Parents
or guardians of participants provided written informed consent.
Data Collection
Cases and controls underwent a standardized clinical assess-
ment that included review of pertinent medical history, respira-
tory ﬁndings, WHO danger signs, comorbidities, and possible
risk factors (eg, lack of immunization and breastfeeding).
Height, weight, and pulse oximetry were measured during a
focused physical examination. Thirty days after enrollment,
cases were reevaluated to ascertain vital status and clinical out-
comes. We deﬁned underweight as weight for age at enrollment
<−2 SD of the median age- and sex-speciﬁc WHO reference;
prematurity as gestational age <37 weeks by parental report;
low birth weight as <2.5 kg or small size at birth by parental
report; HIV-infected as either positive virological test or HIV
seropositive if >12 months old. We deﬁned HIV uninfected-
exposed as an infant or child with a negative virologic test for
HIV who had evidence of HIV exposure, deﬁned as HIV sero-
positive (if <12 months of age), or seronegative with a maternal
history of HIV infection (for all ages), with the caveat that
maternal exposure must be conﬁrmed by maternal serology
for seronegative infants aged <7 months.
Pertussis vaccine administration dates were collected from
vaccination cards, when available, or by maternal history
when the card was unavailable. Whole-cell pertussis vaccine
was used at all sites except South Africa where acellular pertussis
vaccine was used. The recommended schedule was 6, 10, and 14
weeks at all sites except The Gambia (2, 3, and 4 months) and
Thailand (2, 4, and 6 months), with a booster at 18 months in
South Africa (Supplementary Table 1A). Vaccination status was
determined by the number of age-appropriate vaccine doses
that were received at least 2 weeks before enrollment or 2
weeks before cough onset (for children with cough); the child
was deemed undervaccinated if fewer doses were received
than recommended for age, and unvaccinated if no doses
were received in this time frame. Children were considered
too young for vaccination if they were unvaccinated and were
enrolled or had onset of cough before 8 weeks (5 sites) or 10
weeks (The Gambia and Thailand) of age. The child’s age
used in this deﬁnition was based on the child’s age 2 weeks
before enrollment or 2 weeks before cough onset (for children
with cough).
Chest radiographs (CXRs) were performed on cases and were
read and adjudicated according to WHO-standardized inter-
pretation procedures by trained readers who were blinded to
the clinical or laboratory ﬁndings [7]. CXR positivity was
deﬁned as consolidation and/or other inﬁltrate.
A blood sample was collected for a complete blood count
(cases only) and HIV antibody testing (cases [all sites except
Bangladesh] and controls [at all sites except Thailand,
Bangladesh, and The Gambia]). Using standardized methods,
induced sputum (IS) was collected from cases only, and a
ﬂocked nasopharyngeal (NP) swab (ﬂexible minitip, Copan)
and a rayon oropharyngeal (OP) swab specimen were collected
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from each case and control; the NP and OP swabs from each
child were placed into the same vial with 3 mL of universal
transport media (UTM; Copan) [8, 9].
NP/OP and IS specimens were tested in-country by multiplex
polymerase chain reaction (PCR) for 33 pathogens, including
the B. pertussis insertion sequence IS481 (FTD Resp 33, Fast-
track Diagnostics, Sliema, Malta) [10]. When >1 IS specimen
was available from a child, only the ﬁrst was included; results
were considered analyzable regardless of sputum quality indica-
tors such as density of epithelial cells by microscopy [11].
Standard PCR curves were generated every 3 months during
the testing phase to calculate pathogen load from PCR cycle
threshold values. All samples positive for B. pertussis by multi-
plex PCR underwent uniplex B. pertussis IS481 and Bordetella
holmesii recA PCR assays at Canterbury Health Laboratories
(Christchurch, New Zealand) [12]. Children with at least 1
sample that tested positive for B. pertussis IS481 and negative
for B. holmesii recAwere regarded as having pertussis infection.
Statistical Analysis
Data collected at each site were entered into an electronic data
capture system maintained by the Data Coordinating Center
(Emmes Corporation, Rockville, Maryland). To be analyzable
as a case or a control in this analysis, at least 1 respiratory
sample had to be tested. The Kruskal–Wallis test was used to
compare quantitative PCR data between pertussis-positive
cases and controls to evaluate whether higher median density
was associated with clinical infection. To compare continuous
and binary characteristics between pertussis-positive and
-negative cases and controls, as applicable, multiple logistic re-
gression adjusted for site, and age where appropriate, was used.
Analyses involving case fatality ratios were restricted to sites
with pertussis-positive cases. Two-sided P values <.05 were
considered signiﬁcant. Analyses were performed using Stata
software version 12.1 and SAS version 9.4.
RESULTS
Overall Pertussis Positivity
A total of 4232 cases and 5325 control children were enrolled in
PERCH during the 24-month study period at each site; data
from 4200 cases (99.2%) and 5196 controls (97.6%) were con-
sidered analyzable for pertussis. Pertussis was detected by PCR
in 53 cases (1.3%; range by site, 0%–2.5%) and 11 control chil-
dren (0.2%; range by site, 0%–0.6%) (adjusted odds ratio [aOR]
for cases vs controls: 5.1; 95% conﬁdence interval [CI], 2.6–9.8;
P < .01) (Table 1). An additional 6 cases and 5 controls had
samples that were PCR positive for B. holmesii, and were not
included in this analysis. Pertussis-positive cases were detected
at all sites except Thailand; positive controls were found in Mali,
South Africa, and Thailand. The preponderance of pertussis
cases (52/53 [98.1%]) and controls (8/11 [72.7%]) came from
Africa. Adjusting for differences in the age distribution of
cases, continent (Africa vs Asia: aOR, 8.8; P = .03) was signiﬁ-
cantly associated with pertussis positivity. Within Africa, site
was not a signiﬁcant determinant of positivity. Among the
300 PERCH cases 1–59 months of age who died in-hospital
and had pertussis testing at all sites combined, 8 (2.7%) tested
positive for pertussis.
Cases 1–5 months of age were signiﬁcantly more likely to be
pertussis positive compared with cases aged 6–59 months (2.3%
vs 0.5%; aOR, 4.4; 95% CI, 2.4–8.4; P < .01); similarly, controls
aged 1–5 months were more likely to be pertussis positive than
their 6- to 59-month-old counterparts (0.5% vs 0.1%; aOR, 5.9;
95% CI, 1.6–22.3; P = .01) (Table 1). Among the 43 pertussis-
positive cases with both NP/OP and IS specimens available,
14 were positive by IS but not NP/OP (32.6%), whereas 2
were positive in the NP/OP but not IS (4.7%); 27 (62.8%)
were positive by both. Similar results were seen when restricting
to cases aged 1–5 months and when restricting to children with
high-quality IS specimen (deﬁned as <10 squamous epithelial
cells per low-power ﬁeld) [11].
Pertussis Among Cases and Controls 1–5 Months of Age
No pertussis-positive cases aged 1–5 months were identiﬁed at
the 2 Asian sites where the proportion of controls undervacci-
nated for age was lower (12.5%) compared with African sites
(23.5%; P < .0001; Table 2). Thus, to identify potential risk fac-
tors for pertussis-associated hospitalized severe and very severe
pneumonia, we compared pertussis-positive cases to controls
(regardless of pertussis status) only at African sites. Pertussis-
positive cases were signiﬁcantly younger than controls (mean,
10.3 vs 15.8 weeks; P < .01) and were more likely to be HIV
uninfected-exposed (31.6% vs 15.2%; aOR, 2.2; 95% CI,
.99–4.76; P = .053), underweight (35.0% vs 7.6%; aOR, 6.3;
95% CI, 3.0–13.0; P < .01), unvaccinated (66.7% vs 21.5%;
aOR, 3.7; 95% CI, 1.5–9.2; P < .01), and too young to be immu-
nized (66.7% vs 14.8%; aOR, 16.1; 95% CI, 4.1–62.6; P < .001)
compared to controls (Table 2). Most (9/14 [64.3%]) of the un-
derweight children were considered either premature or low
birth weight; however, the association between underweight
and pertussis case status remained signiﬁcant after adjusting
for prematurity and low birth weight. Pertussis-positive cases
were more likely to have never been breastfed compared with
controls (25.0% vs 9.0%; aOR, 2.5; 95% CI, 1.0–6.0; P = .05),
but this association was no longer signiﬁcant when HIV infec-
tion/exposure was included in the model (OR, 1.82; P = .24).
Most pertussis-positive cases (26/40 [66.7%]) were unvaccinat-
ed, all because they were age-ineligible 2 weeks before cough
onset (Table 2). Pertussis-positive cases had a trend toward
higher median density of B. pertussis than pertussis-positive
controls (P = .07; Table 3; Supplementary Figure 1).
We also performed case-case comparisons at the African sites
to identify factors that might distinguish pertussis-positive from
negative cases of severe or very severe pneumonia. Compared to
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cases testing negative, pertussis-positive cases were signiﬁcantly
younger, more likely to be unvaccinated (66.7% vs 39.8%; aOR,
2.8; P = .02; Figure 1; Table 2) and more likely to have ﬁndings
classically associated with pertussis disease (prolonged cough
longer than 7 or 14 days, no audible wheeze, vomiting, leukocy-
tosis ≥20 000 cells/µL, and lymphocytosis ≥10 000 cells/µL;
Table 1. Study Participants Enrolled and Tested for Bordetella pertussis, Percentage Positive by Age and Site, and Case Fatality Ratio Among Pertussis-
Positive Cases
Age Group GAM KEN MAL SAF ZAM BAN THA Total
1–5 mo
No. enrolled
Case 259 209 307 458 327 136 38 1734
Control 199 234 247 365 310 221 91 1667
No. with analyzable specimen
Case 256 208 307 455 321 136 38 1721
Control 189 231 247 363 275 221 91 1617
Reason excludeda
Case A:1, D:1, E:1 B:1 None C:2, E:1 B:4, E:2 None None A:1, B:5, C:2, D:1, E:4
Control D:2, E:7; F:1 E:2, F:1 None E:2 E:35 None None D:2, E:46, F:2
No. Bp+ (%)
Case 3 (1.2) 2 (1.0) 8 (2.6) 18 (4.0) 9 (2.8) 0 0 40 (2.3)
Control 0 0 2 (0.8) 4 (1.1) 0 0 2 (2.2) 8 (0.5)
No. Bp+ in NP-OP only/IS only/both
Caseb 0/1/2 0/1/1 2/0/6 1/4/13 4/4/1 . . . . . . 7/10/23
No. Bp+ cases who died (%)c
Case 0 0 1 (12.5) 3 (16.7) 1 (11.1) . . . . . . 5 (12.5)
6–59 mo
No. enrolled
Case 379 425 367 462 290 389 186 2498
Control 455 631 478 599 376 551 568 3658
No. with analyzable specimen
Case 370 424 366 462 282 389 186 2479
Control 432 626 477 596 335 547 566 3579
Reason excludeda
Case A:1; B:4; E:4 B:1 E:1 None B:4; E:4 None None A:1; B:9; E:9
Control D:3; E:18, F:2 E:3, F:2 E:1 E:3 E:41 E:4 E:2 D:3, E:72, F:4
No. Bp+ (%)
Case 1 (0.3) 2 (0.5) 2 (0.5) 5 (1.1) 2 (0.7) 1 (0.3) 0 13 (0.5)
Control 0 0 2 (0.4) 0 0 0 1 (0.2) 3 (0.1)
No. Bp+ : NP-OP only/IS only/both
Caseb 0/1/0 0/2/0 1/0/1 1/2/2 1/1/0 0/0/1 . . . 3/6/4
No. Bp+ cases who died (%)d
Case 0 0 1 (50.0) 1 (20.0) 1 (50.0) 0 . . . 3 (23.1)
1–59 mo
No. enrolled
Case 638 634 674 920 617 525 224 4232
Control 654 865 725 964 686 772 659 5325
No. Bp+ (%)
Case 4 (0.6) 4 (0.6) 10 (1.5) 23 (2.5) 11 (1.8) 1 (0.2) 0 (0.0) 53 (1.3)
Control 0 (0.0) 0 (0.0) 4 (0.6) 4 (0.4) 0 (0.0) 0 (0.0) 3 (0.5) 11 (0.2)
No. Bp+ cases who died (%)
Case 0 (0.0) 0 (0.0) 2 (20.0) 4 (17.4) 2 (18.2) 0 (0.0) . . . 8 (15.1)
Case-control comparisons of Bp positivity: all P < .05.
Abbreviations: BAN, Bangladesh; Bp, Bordetella pertussis; GAM, The Gambia; IS, induced sputum; KEN, Kenya; MAL, Mali; NP, nasopharyngeal; NP-OP, nasopharyngeal-oropharyngeal swab;
PCR, polymerase chain reaction; SAF, South Africa; THA, Thailand; ZAM, Zambia.
a Reasons for exclusion: A: met exclusion criteria for IS collection and NP PCR result not available; B: died before specimen collected; C: child could not produce specimen; D: other; E: unknown
reason for missing IS and/or NP PCR results; F: parent/guardian refused.
b Applicable to cases only as IS not collected for controls.
c Of the 35 Bp-positive cases aged 1–5 months discharged alive, 21 (60%) had the 30-day follow-up completed and all cases were alive.
d Of the 10 Bp-positive cases aged 6–59 months discharged alive, 9 (90%) had the 30-day follow-up completed and all cases were alive.
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Table 2. Characteristics of Cases and Controls Aged 1–5 Months by Pertussis Status
Characteristic
Cases, No. (%)
Pertussis-
Positive vs
-Negative
Casesa Controls, No. (%)
Pertussis-
Positive Cases vs
Controlsb
Pertussis
Positive (n = 40)
Pertussis
Negative
(n = 1507)
Pertussis
Negative
(n = 174) aORc
P
Valuec
All Africa
(n = 1305)
All Asia
(n = 312)
Pertussis
Positive (n = 8) aORc P Valuec
Africa Africa Asia Africa Africa Asia
Mali, South
Africa, Thailand Africa
Age, wk, mean (SD) 10.3 (6.6) 12.9 (6.0) 14.2 (5.8) . . . .012 15.8 (5.9) 18.2 (5.0) 12.6 (7.2) . . . <.0001**
≤3 mo old 33 (82.5) 1078 (71.5) 114 (65.5) 1.78 .17 684 (52.4) 107 (34.3)* 5 (62.5) 3.87 .001**
Female 15 (37.5) 652 (43.3) 56 (32.2) 0.71 .31 657 (50.3) 154 (49.4) 4 (50.0) 0.58 .10
Never breastfed 10 (25.0) 175 (11.7) 8 (4.6) 1.84 .15 117 (9.0) 4 (1.3)* 0 (0.0) 2.47d .05**
Underweighte 14 (35.0) 388 (25.8) 36 (20.7) 1.72 .12 98 (7.6) 22 (7.1) 2 (25.0) 6.30 <.0001**
Premature or low birth
weightf
13 (33.3) 388 (26.0) 59 (34.1) 1.58 .19 258 (19.9) 51 (16.4) 0 (0.0) 2.02 .052
HIV-infectedg 3 (7.5) 109 (7.2) 1 (0.6) 0.81 .74 65 (5.0) 0 (0.0)* 0 (0.0) 1.05 .93
HIV uninfected-exposedh 12 (31.6) 244 (18.5) 0 (0.0) 1.43 .38 166 (15.2) 0 (0.0)* 1 (12.5) 2.17 .053
Pertussis vaccinationi
Total
Missing Vaccination
data
1 (2.5) 43 (2.9) 3 (1.7) 0.82 .85 18 (1.4) 1 (0.3) 1 (12.5) 1.30 .80
Immunization record
available
31 (79.5) 1255 (85.7) 155 (90.6) 0.35 .09 1184 (92.1) 306 (98.4)* 5 (71.4) 0.19 .0002**
Undervaccinated for
age (any dose)
3 (7.7) 221 (15.1) 14 (8.2) 0.45 .18 302 (23.5) 39 (12.5)* 0 (0.0) . . . . . .
0 doses
Total not vaccinated 26 (66.7) 583 (39.8) 56 (32.8) 2.82 .02 276 (21.5) 30 (9.7) 2 (28.6) 3.69 .005**
Too young 26 (66.7) 502 (34.3) 51 (29.8) 8.09 .001 190 (14.8) 25 (8.0) 2 (28.6) 16.06 <.0001**
Undervaccinated for
age
0 (0.0) 81 (5.5) 5 (2.9) . . . . . . 86 (6.7) 5 (1.6) 0 (0.0) . . . . . .
1 dose
Total 1 dose 6 (15.4) 414 (28.3) 54 (31.6) . . . . . . 337 (26.2) 74 (23.8) 3 (42.9) . . . . . .
Undervaccinated for
age
1 (2.6) 65 (4.4) 8 (4.7) . . . . . . 89 (6.9) 9 (2.9) 0 (0.0) . . . . . .
2 doses
Total 2 doses 3 (7.7) 290 (19.8) 31 (18.1) . . . . . . 359 (27.9) 100 (32.2) 1 (14.3) . . . . . .
Undervaccinated for
age
2 (5.1) 75 (5.1) 1 (0.6) . . . . . . 127 (9.9) 25 (8.0) 0 (0.0) . . . . . .
3 doses
Total 3 doses 4 (10.3) 177 (12.1) 30 (17.5) . . . . . . 315 (24.5) 107 (34.4) 1 (14.3) . . . . . .
Abbreviations: aOR, adjusted odds ratio; BAN, Bangladesh; GAM, The Gambia; HIV, human immunodeficiency virus; KEN, Kenya; MAL, Mali; OR, odds ratio; SAF, South Africa; SD, standard
deviation; THA, Thailand; ZAM, Zambia.
a Pertussis-positive cases compared to negative cases, restricted to Africa.
b Pertussis-positive cases compared to all controls (regardless of pertussis status), restricted to Africa.
c Odds ratios and P values from logistic regressionmodels adjusted for site. Odds ratio for “underweight,” “premature or low birth weight,” “total not vaccinated,” and “too young” adjusted for
site and age in weeks.
d All 10 pertussis-positive cases who were never breastfed were from South Africa; 8 of 10 were HIV exposed. When HIV exposure is included in the model, lack of breastfeeding is no longer
significantly associated with pertussis case status, compared to African controls (OR, 1.82; P= .24). Due to limited numbers, we cannot evaluate the association between breastfeeding and
pertussis case status in the absence of HIV exposure.
e Underweight defined as weight for age <−2 SD of the median age-/sex-specific World Health Organization reference. Remained independently associated with pertussis case status,
compared to African controls, after adjusting for age, site, and prematurity or low birth weight (OR, 6.13; P < .0001).
f Prematurity was defined as gestational age <37 weeks by parental report. Low birth weight was defined as <2.5 kg or small size at birth by parental report. No longer associated with pertussis
case status, compared to African controls, after adjusting for age, site, and underweight (OR, 1.18; P = .68).
g HIV-infected defined as detectable viral load or HIV seropositive if >12 months old.
h HIV uninfected-exposed defined as an infant or child with a negative virologic test for HIV who had evidence of HIV exposure, defined as HIV seropositive (if <12 months of age), or
seronegative with a maternal history of HIV infection (for all ages), with the caveat that maternal exposure must be confirmed by maternal serology for seronegative infants aged <7 months.
i
‘Total not vaccinated’ based on number of doses received at 2 weeks prior to enrollment (for children without cough) or at 2 weeks prior to start of cough (for children with cough). ‘Too young’
defined as zero doses and age two weeks prior to enrollment or age two weeks prior to cough onset ≤8 weeks (KEN, MAL, ZAM, SAF, BAN) or ≤10 weeks (GAM, THA). ‘Under-vaccinated for
age’ defined as the following: Age >8, >12 or >16 weeks with zero, one or two doses, respectively (KEN, MAL, ZAM, SAF, BAN); Age >10, >16 or >18 weeks with zero, one or two doses,
respectively (GAM); Age >10, >18 or >26 weeks with zero, one or two doses, respectively (THA). Age based on age two weeks prior to enrollment or two weeks prior to cough onset.
* Significant (P < .05) difference comparing controls from Africa vs Asia (regardless of pertussis status) using logistics regression models or Fisher exact test; “underweight,” “total not
vaccinated,” and “too young” adjusted for age in weeks.
**P≤ .05.
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Table 3). Fifty-nine percent of pertussis-positive cases and 47.0%
of pertussis-negative cases had radiographic pneumonia (P = .23).
A small fraction (1.1% [8/701]) of controls aged 1–5 months
in Mali, South Africa, and Thailand tested positive for pertussis;
none were detected at the other sites. Compared to pertussis-
negative controls at those sites in this age strata, pertussis-
positive controls were signiﬁcantly more likely to have fever,
vomiting, or tachypnea (all P < .05; Table 3; Supplementary
Table 2), conceivably manifestations of clinically mild pertussis.
Pertussis Mortality in Cases 1–5 Months of Age
The in-hospital case fatality ratio of pertussis-positive cases
aged 1–5 months (12.5%; 95% CI, 4.2%–26.8% [5/40]) was
not signiﬁcantly different than that of pertussis-negative cases
(8.8%; 95% CI, 7.4%–10.3% [132/1507]; P = .43). Deaths of
pertussis-positive cases occurred in Zambia, Mali, and South
Africa (Table 1). Among cases discharged alive, 30-day vital sta-
tus was available for 60.0% (21/35) of pertussis-positive (with
no additional deaths documented) compared with 84.6% of
Table 3. Association of Clinical, Laboratory, and Radiographic Findings With Pertussis Status Among Cases and Controls Aged 1–5 Months
Characteristic
Casesa Controlsb
Pertussis Positive
(n = 40)
Pertussis Negative
(n = 1507)
Pertussis
Positive vs
Negative
Pertussis Positive
(n = 8)
Pertussis
Negative (n = 693)
Pertussis
Positive vs
Negative
No. (%) No. (%) aORc P Valuec No. (%) No. (%) aORc
P
Valuec
Africa Mali, South Africa, Thailand
Runny nose, by report 12 (30.0) 552 (36.6) 0.69 .33 2 (28.6) 82 (11.9) 2.87 .28
Coughd 40 (100.0) 1437 (95.4) . . . .26 2 (25.0) 68 (9.8) 3.58 .14
Cough ≥ 7 d 18 (48.7) 228 (16.3) 5.0 <.0001* 0 (0.0) 10 (15.2) . . . . . .
Cough ≥ 14 d 10 (27.0) 77 (5.5) 6.3 <.0001* 0 (0.0) 1 (1.5) . . . . . .
Duration of cough, d, median
(IQR)e
5 (3–14) 3 (2–5) . . . .004* 4 (3–5) 3 (2–5) . . . .56
Feverd 29 (72.5) 1168 (77.5) 1.02 .97 2 (25.0) 13 (1.9) 19.45 .004*
Vomitingd 14 (35.0) 266 (17.7) 2.55 .006* 1 (14.3) 1 (0.1) 151.50 .0009*
Unable to feedd 9 (22.5) 234 (15.5) 1.54 .27 0 (0.0) 0 (0.0) . . . . . .
Tachypneaf 28 (70.0) 1172 (78.7) 0.63 .20 4 (50.0) 108 (16.9) . . . . . .
Hypoxiag 26 (65.0) 721 (48.0) 1.49 .29 . . . . . . . . . . . .
Stridor 1 (2.5) 34 (2.3) 0.95 .96 . . . . . . . . . . . .
Grunting 7 (18.4) 351 (23.4) 0.62 .33 . . . . . . . . . . . .
Nasal flaring 32 (80.0) 1060 (70.5) 1.38 .44 . . . . . . . . . . . .
Deep breathing 2 (5.0) 194 (12.9) 0.38 .19 . . . . . . . . . . . .
Audible wheeze 0 (0.0) 104 (6.9) . . . .11 . . . . . . . . . . . .
CXR positive 23 (59.0) 664 (47.0) 1.50 .23 . . . . . . . . . . . .
WBC, × 1000 cells/µL, median
(IQR)
19.6 (14.2–34.1) 12.6 (9.1–16.7) . . . <.0001* . . . . . . . . . . . .
WBC≥ 20 ×103 cells/µL 18 (46.2) 216 (15.2) 4.6 <.0001* . . . . . . . . . . . .
Lymphocyte count ×103 cells/
µL, median (IQR)
10.5 (6.1–21.5) 5.9 (4.1–8.2) . . . <.0001* . . . . . . . . . . . .
Lymphocyte count≥ 10 ×103
cells/µL
20 (52.6) 179 (12.9) 7.2 <.0001* . . . . . . . . . . . .
Pertussis NP/OP PCR log
copies/mL, median (IQR)h
7.4 (6.2–8.4) . . . . . . . . . 5.2 (3.8–7.7) . . . . . . . . .
“. . .” Represents variables that were not assessed among controls (hypoxia, stridor, grunting, nasal flaring, deep breathing, audible wheeze) or were measured among too few controls to
allow meaningful comparison (WBC, lymphocytes).
Abbreviations: aOR, adjusted odds ratio; CXR, chest radiograph; IQR, interquartile range; NP/OP, nasopharyngeal/oropharyngeal; PCR, polymerase chain reaction; WBC, white blood cell.
a Analysis restricted to sites with at least 1 pertussis-positive case (Kenya, The Gambia, Zambia, Mali, and South Africa).
b Restricted to sites with at least 1 pertussis-positive control (Mali, South Africa, and Thailand).
c Odds ratios and P values from logistic regression models adjusted for site. After adjusting the WBC and lymphocyte counts for age, there was a minor change in the odds ratios (WBC, 4.8;
lymphocyte, 7.7), but no change in P value.
d By history and/or physical examination. For fever, 12.5% of pertussis positive cases aged 1–5 months had documented fever; the remaining were based on reported fever.
e Restricted to children with cough by history and/or physical examination. Duration in days.
f Respiratory rate >60 breaths/minute if aged <2 months, >50 breaths/minute if aged 2–5 months.
g A child was considered to be hypoxic if (1) a room air pulse oximetry reading indicated oxygen saturation <90% at the 2 sites at elevation (Zambia and South Africa) or <92% at all other sites, or
(2) a room air oxygen saturation reading was not available and the child was on oxygen.
h Median pertussis PCR log copies/mL not significantly different comparing pertussis-positive cases to pertussis-positive controls (P = .07, Kruskal–Wallis test).
*P≤ .05.
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1375 pertussis-negative cases. A sensitivity analysis that takes
into consideration cases not tested for B. pertussis and the
possible outcomes of cases who did not complete a 30-day
follow-up visit is included in the Supplementary Appendix.
The 5 pertussis-positive deaths accounted for 3.7% of the 137
in-hospital PERCH deaths at the 5 African sites among infants
1–5 months of age who were tested for pertussis. All 5 fatal cases
had an inﬁltrate on CXR, elevated white blood cell (WBC) count
(mean, 50.2 × 103 cells/µL; range, 14.2–70.0 × 103 cells/µL),
including 4 cases with WBC > 40 × 103 cells/µL; most were
very young (mean age, 13.0 weeks; range, 7–25 weeks), and 1
was HIV positive. All had multiple potential etiologic pathogens
detected on both NP/OP and IS, as did most infants without
pertussis infection (Supplementary Table 3). Only 1 of the per-
tussis-positive infants who died had received 3 doses of
pertussis vaccine at least 2 weeks prior to cough onset. In con-
trast to the other infants who died, this infant did not manifest a
leukemoid reaction (WBC count was 14.2 × 103 cells/µL in the
single sample tested); this infant presented with cough for 15
days, and was HIV exposed and severely underweight.
Pertussis Among Cases and Controls 6–59 Months of Age
Among PERCH cases (n = 2477) and controls (n = 3564) 6–59
months of age with specimens tested for pertussis, 13 cases
(0.5%) and 3 controls (0.1%) were positive. Compared with per-
tussis-negative cases, pertussis-positive cases were more likely to
report cough of ≥7 days, inability to feed, leukocyte count
≥20 000 cells/µL, and lymphocyte count ≥10 000 cells/µL (all
P < .05) (Supplementary Table 4). Three of the 13 pertussis-
positive cases 6–59 months died (23.1%); 1 child was fully vac-
cinated, the second was HIV-positive and had received only a
single pertussis vaccination, and the third child was unimmu-
nized (clinical ﬁndings are shown in Supplementary Table 3).
These 3 cases accounted for 1.9% of the 158 in-hospital deaths
at the African sites in this age group.
DISCUSSION
The PERCH study identiﬁed B. pertussis as a potential etiologic
agent in a small fraction of severe or very severe pneumonia
cases among hospitalized children 1–59 months of age in
the participating low- and middle-income African and Asian
countries. Pertussis was found in just 2.3% of pneumonia
cases <6 months of age at all sites combined, and in 3.7% of
the in-hospital deaths in this age group. Nonetheless, pertus-
sis-infected cases suffered a considerable risk of death (12.5%
among infants <6 months of age). In comparison, pertussis
was identiﬁed in 0.5% of cases 6–59 months of age, 23.1% of
whom died. Whereas limited access to interventions needed
to manage severe respiratory infections undoubtedly contrib-
utes to mortality from severe pertussis in low resource settings,
[13, 14] case-fatality rates as high as 9% have been reported for
young infants with severe pertussis even in facilities with
advanced critical care; these deaths are often attributed to pul-
monary hypertension, necrotizing bronchopneumonia, cardiac
failure, shock, and multisystem organ dysfunction [15–17].
We identiﬁed 4 risk factors for pertussis infection in PERCH
cases compared to controls. The strongest factor was lack of vac-
cination, which increased the odds of pertussis 3.7-fold, and was
unanimously attributed to the child being too young to receive
vaccine. Other signiﬁcant factors were young age, underweight
and perinatal HIV exposure. These risk factors for severe
pertussis likely reﬂect the commonality that young infants
with insufﬁcient immunity to pertussis are at risk for severe
disease as long as pertussis is circulating in the community
[18]. Accordingly, low birth weight due to prematurity, with
its associated reduced transfer of speciﬁc maternal antibody,
likely characterizes many of the young infants considered to
Figure 1. Cumulative age distribution of children with severe or very severe pneu-
monia by pertussis infection status as determined by polymerase chain reaction
(PCR) results. A, Children with a positive PCR result for pertussis (n = 53). B, Children
whose PCR results were negative (n = 4120). Pertussis-positive children were signifi-
cantly younger than pertussis-negative children (median, 2 vs 7 months; P = .01, lo-
gistic regression adjusted for site, restricted to sites in Africa and Bangladesh where
positive cases were found).
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be underweight in our study. Similarly, HIV uninfected-
exposed newborns have been shown to acquire signiﬁcantly
lower levels of pertussis maternal antibody compared with
unexposed infants [19], and in South Africa have a higher like-
lihood of pertussis-associated pneumonia requiring hospitaliza-
tion [18].
We observed disparities in pertussis prevalence at the African
compared with the Asian sites. This may be attributed, at least
in part, to the higher rate of HIV exposure, undernutrition, low
birth weight, and prematurity among African infants, all risk
factors for pertussis [13]. South Africa, the site with the highest
percentage of pertussis-positive cases, had the lowest (73%)
coverage with 3 pertussis vaccine doses in the community as
estimated from controls aged 9–18 months. Moreover, South
Africa was the only site using acellular pertussis vaccine,
which has lower estimates of both short-term and long-term
efﬁcacy compared with whole cell vaccine [21, 22]. Vaccine
coverage was highest (>95%) in the 2 Asian sites that had no
pertussis-positive cases among infants <6 months of age,
which may have reduced transmission via herd immunity (Sup-
plementary Table 1B).
Our study provides insights into pertussis diagnostics. First,
there was strong agreement between NP/OP and IS results,
although pertussis was detected more frequently from IS than
from NP/OP specimens as seen elsewhere [18, 23]; IS increased
detection above NP/OP alone by 48% among children with both
specimens collected. If the added contribution of IS is mainly
because it provides another respiratory sample, we would expect
the proportion of NP-negative/IS-positive and NP-positive/IS-
negative cases to be about the same, which was not the case.
Second, the density of pertussis in the NP/OP, as measured in
copies per milliliter, was higher in the pertussis-positive cases
than the pertussis-positive controls, suggesting that greater den-
sity may be associated with disease manifestations. There have
been concerns about the speciﬁcity of PCR for B. pertussis [24],
especially the ability to also detect B. holmesii, a bacterium with
uncertain clinical signiﬁcance that has been associated with per-
tussis-like respiratory infections in humans [25]. Consequently,
we excluded all IS481 PCR-positive samples that also tested
positive with a B. holmesii–speciﬁc PCR assay. In contrast to
other studies that found few, if any, positive for B. holmesii
[18, 26], we found that 17% of samples (11/66) that were posi-
tive for pertussis among the cases and controls in the multiplex
PCR assay were excluded on this basis.
The highly sensitive nature of multiplex PCR leads to
identiﬁcation of multiple potential pathogens of uncertain sig-
niﬁcance in many children. Etiologic attribution, based on path-
ogens detected among both the cases and controls is the subject
of a separate PERCH report. Therefore, correlation of PCR with
clinical ﬁndings is of great interest in this descriptive analysis.
Notably, several clinical ﬁndings observed among our pertussis
cases are atypical, such as the high prevalence of fever among
infants 1–5 months old, which may reﬂect coinfecting patho-
gens and/or the reliance on maternal report (only 17% of in-
fants actually had medically documented fevers). In addition,
the duration of cough was brief (<7 days) in approximately
25% of cases. Some case deﬁnitions of pertussis for infants 0–
3 months old disregard cough duration; however, cough must
be accompanied by classic posttussive events such as apnea,
vomiting, cyanosis, seizures, or deep inspiratory whoop, fea-
tures that add speciﬁcity to the diagnosis [27]. A limitation of
our study is that the quality of the cough was not interrogated,
and we did not inquire of parents whether vomiting was post-
tussive or unrelated to coughing. It is therefore reassuring that
among the cases aged 1–5 months, those who were B. pertussis
positive were signiﬁcantly more likely than uninfected cases to
have features highly characteristic of pertussis, such as elevated
total WBC count with lymphocytosis, a cough lasting ≥7 or ≥14
days, and vomiting [16, 28–30]. Moreover, all had a clinical di-
agnosis of pneumonia, a diagnostic criterion for pertussis [27].
We intentionally did not estimate the vaccine effectiveness of
infant pertussis vaccination. Case-control studies of vaccine
effectiveness must strive to collect immunization data from all
cases and controls in the same manner and aim for the greatest
degree of documentation and completeness. As estimating
vaccine effectiveness was not the objective of PERCH, the
vaccination records were not collected in this manner. Further-
more, as controls were usually enrolled at home, where records
were more often available, compared with cases, who were
enrolled at hospitalization, there is a difference in the source
and possibly validity of the vaccination history of cases and
controls (Supplementary Table 1A and 1B).
The contribution of pertussis to pneumonia mortality in the
PERCH study (2.7%), when applied to global estimates of the
contribution of pneumonia to all-cause mortality in 2013
(15% in those 0–59 months of age [2]), leads to an estimate
of the global pertussis contribution (0.4%) that can be com-
pared with the current estimate of the pertussis contribution
to overall childhood mortality (ie, 1% of all-cause deaths in chil-
dren aged 0–59 months, inferred from an estimate of 60 000
pertussis deaths), which is based on a natural history model
[2]. There are several reasons why the burden implied by
PERCH might be inaccurate. The PERCH study assessed hospi-
talized children only and did not enroll infants in the ﬁrst
month of life, an age group contributing a sizeable number of
the deaths among children <5 years of age, and one that is at
risk for pertussis [31]. If the fraction of deaths in those 2 groups
attributable to pertussis is substantially higher or lower than the
observed 2.7% of deaths in PERCH, the estimate of the pertussis
contribution to global deaths will increase or decrease. Further-
more, the respiratory syndrome meeting the PERCH case
deﬁnition is not the only clinical presentation of pertussis; it
can also present with encephalitis, cerebral hemorrhage, pulmo-
nary hypertension [32], or apnea [33], and many cases manifest
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persistent cough that is paroxysmal, with or without an inspira-
tory whoop and posttussive apnea and/or vomiting. Finally,
because the incidence of pertussis varies over time (tending to
produce peaks every 2–5 years) [34], and geography [35], the
study duration of 24 months at each site did not likely capture
the full spectrum of disease burden for that particular site, but
collectively may be largely representative as PERCH study data
collection took place over a 30-month period. Therefore, the
burden detected in PERCH, although likely capturing most of
the serious pertussis burden, is not exhaustive [13, 36, 37].
In conclusion, the PERCH study demonstrated that pertussis
causes a small fraction of severe or very severe hospitalized
pneumonia and associated deaths during the postneonatal peri-
od. Nonetheless, in the African sites, approximately 1 in 10 of
pertussis-infected hospitalized cases died. The risk factors we
have identiﬁed point the way toward interventions that could
impact this disease burden. Strategies to reduce pertussis circu-
lation through complete infant and childhood vaccination
should be emphasized, as achieving reductions in the other
risk factors (eg, preterm and underweight births, undernutri-
tion, and maternal HIV infection) is a long-term development
challenge. The occurrence of pertussis in young, unvaccinated
infants and in those at risk for diminished levels of maternal
antibody suggests that maternal vaccination could also be a
targeted strategy to further reduce disease burden. Recent ob-
servations that early second-trimester maternal acellular pertus-
sis immunization signiﬁcantly increased neonatal antibodies
compared with third-trimester vaccination offer a potential
strategy to improve immunity in premature infants [38]. The
PERCH pertussis data contribute to the more comprehensive
understanding of pertussis infection in low-resource settings
and advance the prioritization of prevention strategies.
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